Wealth destroyer, page-114

I will expand on my theory for you ax. Lets look at the only other two outcomes that were available at the mid term phase 2 hsv 2 results. As you know we came in at 58% reduction in viral shedding which is pretty much identical to Genocea 003 results.
If we had come in under their 58% reduction our share holders may have thrown their hands up in the air and said why continue if we are behind. The company did not want this. Also it would be hard for a vax partner to justify to it's constituents as to the varsity of a partnership with the company in second place. The company did not want this either.
If we had come in above Genocea's 58% then people would be saying that the professor and his team had succeeded and the share price would have spiked. The company also did not want this.
The partner needs a low share price with good news ahead, not a high share price with good news behind. The incentive for the partner is to come in cheap and ride the spike delivered from up coming announcements.
That is why I theorise that it was crucial for the vax results to come in exactly the same as Genocea's as to walk the balance between expectations and a share price spike. I am expecting a partnership at a low price followed by improvement in hsv 2 vax results and all aspects of our business.